Clinical implication of biomarker for patients with acute stroke

分泌型晚期糖基化终产物受体(SRAGE)包括sRAGE和内源性sRAGE(EsRAGE)。五羟色胺是一种高级糖基化终产物(AGE)。凝集素样氧化型低密度脂蛋白受体1负责氧化低密度脂蛋白的摄取，并以可溶性形式部分释放到血清中(sLOX-1)。很少有研究探讨AGEs-RAGE系统或sLOX-1在急性中风患者中的关键作用。我们检测了与急性卒中临床特征相关的血浆sRAGE/esRAGE、五羟色胺和sLOX-1水平。血浆sRAGE和esRAGE水平均与估计的肾小球滤过率相关。急性卒中患者血浆戊四氮水平较正常升高。以114pm o l/m L为临界值，对急性卒中的敏感性(0.798)和特异性(0.800)均较高。发病一周内sLOX-1水平升高，3个月后sLOX-1水平下降。

A secreted isoform of receptor for advanced glycation end products (sRAGE) involves sRAGE and endogenous sRAGE (esRAGE). Pentosidine is one of an advanced glycation end product (AGE). Lectin-like oxidized LDL receptor 1 is responsible for the uptake of oxidized LDL and is released to serum in part as the soluble form (sLOX-1). Few studies addressed the pivotal roles of the AGEs-RAGE system or sLOX-1 in acute stroke patients. We measured plasma sRAGE/esRAGE, pentosidine, and sLOX-1 levels associated with clinical features in acute stroke. Both plasma sRAGE and esRAGE levels correlated with estimated glomerular filtration rate. Higher levels of plasma pentosidine compared with normal were demonstrated in patients with acute stroke. The cut off value 114 pmol/mL of pentosidine has high sensitivity (0.798) and specificity (0.800) for acute stroke. High level of sLOX-1 was examined within a week after the onset of ischemic stroke, however, they decreased at 3 month.